Nissan Halts Electric Qashqai Development Amid EV Market Challenges 
Cerebras Revenue Forecast Tops Expectations, but Margin Concerns Weigh on Stock 
Tencent Reviews Marvelous Stake as Gaming Giant Reassesses Global Investment Strategy 
Heineken Names JDE Peet’s CEO Rafael Oliveira as New Chief Executive 
Samsung Electronics Stock Surges on Report of Massive $59 Billion Share Buyback Plan 
SK Hynix Targets $29.4 Billion Nasdaq Listing to Expand AI Chip Business 
Ryan Cohen Rejects GameStop Pay Package, Prepares New eBay Acquisition Plan 
Anthropic AI Model Uncovers Vulnerabilities in Classified U.S. Government Systems During Security Test 
Doncasters Raises $919 Million in NYSE IPO as Aerospace Growth Accelerates 
Fortescue Faces Class Action Over Sexual Harassment Claims at Australian Mining Sites 
Meta Reportedly Developing ‘Arena’ Prediction Market App to Rival Polymarket and Kalshi 
Trip.com Shares Tumble After Q1 Profit Drops and Weak Revenue Growth Outlook 
Alibaba Shares Fall After Anthropic Alleges Massive AI Model Distillation Campaign 
FedEx Stock Drops After Weak 2026 Earnings Forecast Despite Strong Q4 Results 
Tesla and NatPower Partner on $5 Billion Battery Storage Expansion in Europe 
DOJ Opens Investigation Into NYC Coffee Shop Over Anti-Goldman Social Media Post 
Micron Stock Surges on Strong AI Demand, Record Revenue, and Bullish Q4 Forecast 
NEW YORK, Feb. 26, 2016 -- The following statement is being issued by Levi & Korsinsky, LLP:
To: All persons or entities who purchased or otherwise acquired securities of INSYS Therapeutics, Inc. (“INSYS”) (NASDAQ:INSY) between March 3, 2015 and January 25, 2016.
You are hereby notified that a securities class action lawsuit has been commenced in the USDC for the District of Arizona. If you purchased INSYS securities between March 3, 2015 and January 25, 2016, your rights may be affected by this action. To get more information go to:
http://zlk.9nl.com/insys-therapeutics
or contact Joseph E. Levi, Esq. either via email at [email protected] or by telephone at (212) 363-7500, toll-free: (877) 363-5972. There is no cost or obligation to you.
The complaint alleges that INSYS made materially false and misleading statements to investors and/or failed to disclose that: (i) the Company was engaged in the illegal and improper off-labeling marketing of Subsys, a cancer pain treatment; (ii) certain INSYS employees were complicit in an illegal kickback scheme operated for the purpose of increasing prescriptions of Subsys; and (iii) as a result, the Company’s financial statements were materially false and misleading at all relevant times.
On January 25, 2016, the Southern Investigating Report Foundation published an article entitled “The Brotherhood of Thieves: Insys Therapeutics,” alleging that INSYS pressured employees to develop new schemes to promote the illegal and inappropriate off-label use and sale of Subsys.
If you suffered a loss in INSYS you have until April 4, 2016 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.
Levi & Korsinsky is a national firm with offices in New York, New Jersey, California, Connecticut, and Washington D.C. The firm’s attorneys have extensive expertise and experience representing investors in securities litigation, and have recovered hundreds of millions of dollars for aggrieved shareholders. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT: Levi & Korsinsky, LLP Joseph E. Levi, Esq. 30 Broad Street - 24th Floor New York, NY 10004 Tel: (212) 363-7500 Toll Free: (877) 363-5972 Fax: (212) 363-7171 www.zlk.com
